VMDHealthcare · Medical DevicesThe 1 Wall Street analysts covering Viemed Healthcare, Inc. hold a median 12-month price target of $11 — +24.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Viemed Healthcare, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (92): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Revisions (52): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on VMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +24.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Aug 2026 | Freedom Broker | Downgrade | Hold | $11 |
| 3 Nov 2021 | RBC Capital | Maintains | Outperform | $13 → $9.00 |
| 3 Nov 2021 | RBC Capital | Maintains | Outperform | — |
| 5 Mar 2021 | RBC Capital | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VMD appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 32% of US stocks
Cheaper than 68% of US stocks
Cheaper than 42% of US stocks
Cheaper than 51% of US stocks
Higher than 74% of US stocks
Higher than 24% of US stocks
Higher than 71% of US stocks
Higher than 58% of US stocks
Higher than 59% of US stocks
Higher than 64% of US stocks
Higher than 88% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Viemed Healthcare, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the transcript of Viemed Healthcare, Inc.'s Q2 2026 earnings call. The transcript covers management's discussion and Q&A from the quarterly earnings presentation.
Why it matters — VMD watchers can read the full transcript of the company's Q2 2026 earnings call to review management commentary on the quarter's results.
Viemed Healthcare reported record second-quarter revenue, driven by resumed growth in its ventilator business under the updated Medicare coverage framework and expanded newer service lines.
Why it matters — A VMD watcher would care because record quarterly revenue signals renewed momentum in the core ventilator business and growth across newer service lines.
Viemed Healthcare reported Q2 earnings of $0.07 per share, falling short of the Zacks Consensus Estimate of $0.10 per share and down from $0.08 per share a year ago.
Why it matters — The earnings miss versus analyst expectations and year-ago results may raise concerns about the company's near-term financial performance.
Viemed Healthcare reported financial results for the three and six months ended June 30, 2026. Net revenues for the quarter were $78.1 million, a Company record, up $15.0 million (23.9%) from the prior-year quarter and about 3.6% sequentially. The Company also updated its guidance for the full year ending December 31, 2026.
Why it matters — A VMD watcher would care because the quarter set a Company revenue record with significant year-over-year growth, and the Company revised its full-year 2026 outlook.
The 1 Wall Street analysts covering Viemed Healthcare, Inc. have a median 12-month price target of $11, with estimates ranging from $11 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Viemed Healthcare, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Viemed Healthcare, Inc. 96 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Viemed Healthcare, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (92 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +24.6% from the last close, and Ticker Nerd's factor model ranks Viemed Healthcare, Inc. 96 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Viemed Healthcare, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $11 over the next 12 months.
Viemed Healthcare, Inc. returned +25.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Viemed Healthcare Inc. operates as a healthcare service provider, specializing in in-home respiratory care and related services.
The most recent item we track (Seeking Alpha, 5 Aug 2026): "Viemed Healthcare, Inc. (VMD) Q2 2026 Earnings Call Transcript". Seeking Alpha published the transcript of Viemed Healthcare, Inc.'s Q2 2026 earnings call. The transcript covers management's discussion and Q&A from the quarterly earnings presentation.
Viemed Healthcare Inc. operates as a healthcare service provider, specializing in in-home respiratory care and related services. Its primary function is to deliver high-quality and personalized healthcare solutions to patients suffering from chronic obstructive pulmonary disease (COPD) and other severe respiratory conditions. Viemed offers a comprehensive suite of services including disease management, ventilator therapy, and robust patient monitoring, ensuring continuity of care beyond traditional clinical settings. The company greatly impacts sectors such as home healthcare and respiratory therapy, positioning itself as a crucial link between hospital care and long-term home-based treatment. Founded with the mission to improve patient quality of life, Viemed leverages advanced technology and a team of skilled respiratory therapists to optimize patient outcomes. In the financial markets, Viemed Healthcare Inc. is recognized for its innovative approach to healthcare delivery, catering to an aging population with increasing demand for home-based chronic care solutions. Based in the United States, Viemed is at the forefront of addressing the growing healthcare needs sustainably and compassionately, reinforcing its significance in the evolving landscape of in-home healthcare services.
CEO Mr. Casey Hoyt · 1,438 employees · United States · https://www.viemed.com